Grifols S.A. Cl B | Income Statement

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,742
3,355
3,935
4,050
4,318
4,487
Cost of Goods Sold (COGS) incl. D&A
1,383
1,764
2,082
2,212
2,246
2,519
Gross Income
1,358
1,591
1,852
1,837
2,072
1,967
SG&A Expense
622
733
882
898
1,068
973
EBIT
736
858
970
939
1,003
994
Unusual Expense
2
21
25
8
4
-
Non Operating Income/Expense
18
18
19
4
34
22
Interest Expense
222
225
234
240
259
293
Pretax Income
499
596
699
706
716
737
Income Tax
155
123
159
168
34
131
Equity in Affiliates
1
7
8
7
20
11
Consolidated Net Income
342
467
531
545
661
594
Net Income
346
470
532
545
663
597
Net Income After Extraordinaries
346
470
532
545
663
597
Net Income Available to Common
346
470
532
545
663
597
EPS (Basic)
0.51
0.69
0.78
0.80
0.97
0.87
Basic Shares Outstanding
681
685
685
683
684
685
EPS (Diluted)
0.51
0.69
0.78
0.80
0.97
0.87
Diluted Shares Outstanding
681
685
685
684
684
685
EBITDA
865
1,047
1,160
1,141
1,219
1,223
Non-Operating Interest Income
5
3
6
10
10
14
Minority Interest Expense
3
3
1
1
1
2

About Grifols

View Profile
Address
Avinguda de la Generalitat, 152-158
Barcelona Catalonia 08174
Spain
Employees -
Website http://www.grifols.com
Updated 07/08/2019
Grifols SA is a vertically integrated global producer of plasma derivatives. Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers. The company operates through the following segments: Bioscience, Hospital, Diagnostic and Raw Materials.